A previous clinical trial found that tamoxifen, taken for five years, reduced the risk of developing invasive breast cancer by about 50% in post-menopausal women who were at increased risk of getting the disease.
Another trial found that five years of raloxifene reduces breast cancer risk in such women by about 38%.
Under the new plans, high risk post-menopausal women could be offered the drugs for a period of five years unless they have a history of thromboembolic disease or endometrial cancer.
More top news
The Duchess of Sussex features on the front pages once again.
Sajid Javid will use his first major speech since his appointment to offer an olive branch to rank-and-file personnel.
A third of water taken from the natural environment in England is wasted, including three billion litres a day from leaky pipes.